insights_auto
Why is ALNY up 3,63%?
Dive Deeperchevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
232,68 US$
arrow_upward
+3,63%(+8,15) 1D
232,68 US$
0,00% (0,00)
bedtimeAfter hours
Closed: 9 ოქტ, 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
224,74 US$
High
232,94 US$
Low
222,70 US$
Mkt. cap
31,13 მლრდ.
Avg. vol.
1,50 მლნ.
Volume
959,45 ათ.
P/E ratio
39,60
52-wk high
495,55 US$
52-wk low
197,81 US$
EPS
5,88 US$
Beta
0,28
Shares outstanding
133,81 მლნ.
No. of employees
2 ათ.
Open
224,74 US$
High
232,94 US$
Low
222,70 US$
Mkt. cap
31,13 მლრდ.
Avg. vol.
1,50 მლნ.
Volume
959,45 ათ.
P/E ratio
39,60
52-wk high
495,55 US$
52-wk low
197,81 US$
EPS
5,88 US$
Beta
0,28
Shares outstanding
133,81 მლნ.
No. of employees
2 ათ.
News stories
From web sources and news partners
Simply Wall Street
·
18 საათის წინ
Alnylam Pharmaceuticals (ALNY) Could Be 37% Undervalued After TTR Sales Probe
Stock Traders Daily
·
19 საათის წინ
(ALNY) Price Dynamics and Execution-Aware Positioning
Yahoo Finance
·
20 საათის წინ
Alnylam vs. Ionis: Here's the Better Bad-News Buy
Zacks
·
1 დღის წინ
argenx Meets Primary Endpoint in Phase II Celiac Disease Study
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.